Published in Hepatitis Weekly, October 7th, 1996
Twinrix is a combined vaccine against hepatitis A (HAV) and B (HBV). The approval applies to all 15 countries in the European Union.
HAV and HBV affect almost every urban and rural community and are among the most common infectious diseases in the world. Both represent serious public health problems: there are, worldwide, an estimated 1.4 million cases of HAV per year and 300 million-350 million chronic carriers of HBV.
The community decision, granting European marketing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (1996-10-07)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.